Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia

Atherosclerosis. 2021 May:324:148-150. doi: 10.1016/j.atherosclerosis.2021.03.026. Epub 2021 Mar 28.

Authors

Paola Sabrina Buonuomo¹, Gerarda Mastrogiorgio², Giovanna Leone³, Ippolita Rana², Michaela Veronika Gonfiantini², Marina Macchiaiolo², Davide Vecchio², Maria Gnazzo⁴, Andrea Bartuli²

Affiliations

¹ Rare Diseases and Medical Genetics, Bambino Gesù Children's Hospital Rome, IRCCS, Italy. Electronic address: psabrina.buonuomo@opbg.net.
² Rare Diseases and Medical Genetics, Bambino Gesù Children's Hospital Rome, IRCCS, Italy.
³ Unit of Transfusion Medicine, Bambino Gesù Children's Hospital Rome, IRCCS, Italy.
⁴ Laboratory of Medical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

PMID: 33824001
DOI: 10.1016/j.atherosclerosis.2021.03.026

No abstract available

Keywords: Evolocumab; Pediatric familial homozygous hypercholesterolemia.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Anticholesteremic Agents* / adverse effects
Child
Humans
Hyperlipoproteinemia Type II* / diagnosis
Hyperlipoproteinemia Type II* / drug therapy
Hyperlipoproteinemia Type II* / genetics
Proprotein Convertase 9

Substances

Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Proprotein Convertase 9
evolocumab